| scholarly article | Q13442814 |
| P2093 | author name string | Alan R Tall | |
| Ira J Goldberg | |||
| Hye-Lim Noh | |||
| Ravichandran Ramasamy | |||
| Chien-Ping Liang | |||
| Yunying Hu | |||
| Reeba K Vikramadithyan | |||
| Kellie Hallam | |||
| P2860 | cites work | Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury | Q46535314 |
| Tissue distribution of mammalian aldose reductase and related enzymes | Q46632413 | ||
| Scavenger receptor expressed by endothelial cells I (SREC-I) mediates the uptake of acetylated low density lipoproteins by macrophages stimulated with lipopolysaccharide | Q47598350 | ||
| Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17beta-estradiol. | Q50865979 | ||
| Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity. | Q51555624 | ||
| Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. | Q51657700 | ||
| Expression of inducible nitric oxide synthase in macrophages and smooth muscle cells in various types of human atherosclerotic lesions | Q59704196 | ||
| Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function | Q70349162 | ||
| Rapid genotyping of low density lipoprotein receptor knockout mice using a polymerase chain reaction technique | Q70893238 | ||
| Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions | Q71995005 | ||
| Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial | Q72198055 | ||
| Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA | Q72258241 | ||
| Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice. Effects on lipoproteins and atherosclerosis | Q73251589 | ||
| Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene | Q77801094 | ||
| Cloning and expression of human aldose reductase | Q24311265 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis | Q28286844 | ||
| Angptl3 regulates lipid metabolism in mice | Q28586080 | ||
| CD36 is a receptor for oxidized low density lipoprotein | Q28678362 | ||
| Class A scavenger receptors, macrophages, and atherosclerosis | Q34372269 | ||
| Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications | Q35181339 | ||
| Oxidative stress in the pathogenesis of diabetic neuropathy | Q35856228 | ||
| Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? | Q35946085 | ||
| Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions | Q37486465 | ||
| Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. | Q38299150 | ||
| Increased CD36 protein as a response to defective insulin signaling in macrophages | Q38344254 | ||
| Why does diabetes increase atherosclerosis? I don't know! | Q39951404 | ||
| Dyslipidemia and diabetes: animal models. | Q40452136 | ||
| Aldose reductase inhibitors: the end of an era or the need for different trial designs? | Q40883198 | ||
| Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts | Q41009444 | ||
| Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-ric | Q41664275 | ||
| Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. | Q41713888 | ||
| Synthetic low and high fat diets for the study of atherosclerosis in the mouse | Q43607933 | ||
| Aldose reductase activation is a key component of myocardial response to ischemia | Q43843299 | ||
| Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice | Q44007466 | ||
| Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein | Q44174326 | ||
| Induction of atherosclerosis by low-fat, semisynthetic diets in LDL receptor-deficient C57BL/6J and FVB/NJ mice: comparison of lesions of the aortic root, brachiocephalic artery, and whole aorta (en face measurement). | Q44542257 | ||
| Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. | Q44552097 | ||
| Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration | Q44745040 | ||
| Redox state-dependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency | Q44767284 | ||
| Central role for aldose reductase pathway in myocardial ischemic injury | Q45000419 | ||
| Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol | Q45042425 | ||
| Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy | Q45081244 | ||
| Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice | Q45120387 | ||
| Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes | Q45158469 | ||
| Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. | Q45158735 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 2434-43 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice | |
| P478 | volume | 115 |
| Q37666671 | 2013 Russell Ross memorial lecture in vascular biology: cellular and molecular mechanisms of diabetes mellitus-accelerated atherosclerosis |
| Q41862984 | Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis |
| Q24313499 | Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates |
| Q100523502 | Aldo-keto reductase family 1 member B induces aortic valve calcification by activating hippo signaling in valvular interstitial cells |
| Q35090344 | Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. |
| Q37751655 | Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. |
| Q37510157 | Aldose reductase drives hyperacetylation of Egr-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals. |
| Q36945298 | Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients |
| Q37100186 | Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore |
| Q35131902 | Aldose reductase pathway contributes to vulnerability of aging myocardium to ischemic injury. |
| Q36543639 | Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice |
| Q46003997 | Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis. |
| Q36777049 | Aldose reductase, oxidative stress and diabetic cardiovascular complications |
| Q35947855 | Aldose reductase, oxidative stress, and diabetic mellitus |
| Q37707000 | Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets |
| Q26822630 | Animal models of diabetic macrovascular complications: key players in the development of new therapeutic approaches |
| Q38785900 | Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial |
| Q48288318 | Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins |
| Q34431401 | Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia. |
| Q39788178 | Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice |
| Q38720113 | Controversies surrounding percutaneous coronary intervention in the diabetic patient |
| Q31124912 | Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes |
| Q37333371 | Diabetes and atherosclerosis: is there a role for hyperglycemia? |
| Q42021514 | Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I |
| Q35849515 | Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. |
| Q36199128 | Diabetic vascular disease and the potential role of macrophage glucose metabolism |
| Q39999962 | Differential regulation of aldose reductase expression during macrophage polarization depends on hyperglycemia |
| Q37083092 | Does Elevated Glucose Promote Atherosclerosis? Pros and Cons |
| Q38271958 | Dynamic Aspects of Macrophage Polarization during Atherosclerosis Progression and Regression |
| Q35653968 | Effects of High Fat Feeding and Diabetes on Regression of Atherosclerosis Induced by Low-Density Lipoprotein Receptor Gene Therapy in LDL Receptor-Deficient Mice |
| Q43093239 | Effects of the New Aldose Reductase Inhibitor Benzofuroxane Derivative BF-5m on High Glucose Induced Prolongation of Cardiac QT Interval and Increase of Coronary Perfusion Pressure. |
| Q36853797 | Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice |
| Q37145896 | Epidemic inflammation: pondering obesity |
| Q33502710 | Exclusion of NFAT5 from mitotic chromatin resets its nucleo-cytoplasmic distribution in interphase |
| Q50118982 | Fat in the Blood, Fat in the Artery, Fat in the Heart: Triglyceride in Physiology and Disease |
| Q34456888 | From metabolomics to fluxomics: a computational procedure to translate metabolite profiles into metabolic fluxes |
| Q92662725 | Glucose Metabolism in Cardiac Hypertrophy and Heart Failure |
| Q35485016 | Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane |
| Q37636425 | Hepatic transforming growth factor-β 1 stimulated clone-22 D1 controls systemic cholesterol metabolism |
| Q56971664 | Human Aldose Reductase Expression Prevents Atherosclerosis Regression in Diabetic Mice |
| Q35753067 | Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein E-/- mice |
| Q57817035 | Hyperglycemia Aggravates Diet-Induced Coronary Artery Disease and Myocardial Infarction in SR-B1-Knockout/ApoE-Hypomorphic Mice |
| Q35830289 | Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. |
| Q37258582 | Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway |
| Q35661984 | Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. |
| Q37325024 | Immune and inflammatory mechanisms of atherosclerosis (*) |
| Q35061758 | Impairment of nitrergic system and delayed gastric emptying in low density lipoprotein receptor deficient female mice. |
| Q41882168 | Incretin hormones as immunomodulators of atherosclerosis. |
| Q38059912 | Inflammation and diabetes-accelerated atherosclerosis: myeloid cell mediators. |
| Q34698887 | Insulin resistance and atherosclerosis |
| Q27011696 | Insulin resistance, hyperglycemia, and atherosclerosis |
| Q52773690 | Insulin resistance: vascular function and exercise. |
| Q33753663 | Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data |
| Q26860086 | Lipids and the endothelium: bidirectional interactions |
| Q35140825 | Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes |
| Q30441275 | Mechanisms by which diabetes increases cardiovascular disease |
| Q28070313 | Molecular Imaging of Vulnerable Atherosclerotic Plaques in Animal Models |
| Q38125279 | Molecular biology of atherosclerosis |
| Q36766171 | Mouse models for studies of cardiovascular complications of type 1 diabetes |
| Q27335174 | Mucosal tolerance to a combination of ApoB and HSP60 peptides controls plaque progression and stabilizes vulnerable plaque in Apob(tm2Sgy)Ldlr(tm1Her)/J mice |
| Q35130806 | Novel role for aldose reductase in mediating acute inflammatory responses in the lung |
| Q34603680 | Nutritional B vitamin deficiency alters the expression of key proteins associated with vascular smooth muscle cell proliferation and migration in the aorta of atherosclerotic apolipoprotein E null mice |
| Q29615423 | Oxidative Stress and Diabetic Complications |
| Q26744840 | Pathogenesis and neuroimaging of cerebral large and small vessel disease in type 2 diabetes: A possible link between cerebral and retinal microvascular abnormalities |
| Q28087462 | Pathogenesis of diabetic cerebral vascular disease complication |
| Q35769224 | Protective Pleiotropic Effect of Flavonoids on NAD⁺ Levels in Endothelial Cells Exposed to High Glucose |
| Q37384331 | Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response |
| Q37400729 | Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue |
| Q42139014 | Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat |
| Q39260228 | Role of nitric oxide in regulating aldose reductase activation in the ischemic heart |
| Q38000380 | Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited |
| Q52666460 | SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice. |
| Q36106728 | SIRT6 Is a Positive Regulator of Aldose Reductase Expression in U937 and HeLa cells under Osmotic Stress: In Vitro and In Silico Insights. |
| Q47094524 | The AGE-RAGE Axis: Implications for Age-Associated Arterial Diseases |
| Q37560012 | The Role of Immunogenicity in Cardiovascular Disease |
| Q38023062 | The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. |
| Q37068700 | The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient |
| Q37464743 | Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials |
| Q34563283 | Type 2 Diabetes: Endothelial dysfunction and Exercise |
| Q30440695 | Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis |
| Q36537262 | Vascular complications of diabetes: mechanisms of injury and protective factors |
| Q34324735 | miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice. |
Search more.